CRISPR Therapeutics AG annual report, FY2021

CRISPR Therapeutics AG — FY2021 Form 10-K

Reporting period: Fiscal year ended December 31, 2021. Although the request identifies 2021 Q4, this is an annual report; the supplied financial results are for the full year, not standalone fourth-quarter results. Amounts below are in U.S. dollars.

Business context

CRISPR Therapeutics is a clinical-stage gene-editing company with no approved products and no product-sale revenue. Its lead program, CTX001, is an ex vivo gene-edited cell therapy for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD), developed with Vertex. Other programs include allogeneic CAR-T candidates, a gene-edited diabetes cell therapy with ViaCyte, and early in vivo programs.

Financial and liquidity highlights

Metric	FY2021	FY2020
Total revenue	$915.0 million	$0.7 million
Collaboration revenue	$913.1 million	$0.5 million
Research and development expense	$438.6 million	$266.9 million
General and administrative expense	$102.8 million	$88.2 million
Operating income (loss)	$373.5 million	$(354.4) million
Net income (loss)	$377.7 million	$(348.9) million
Operating cash flow	$539.0 million	$(238.4) million

• FY2021 collaboration revenue included a $900 million upfront payment tied to the amended Vertex agreement and $12.0 million of revenue recognized from a $12.5 million milestone under the separate 2019 Vertex collaboration. The company has not generated product-sale revenue.
• Reported operating margin was approximately 40.8% (operating income divided by total revenue), but it is heavily affected by the one-time collaboration payment and should not be read as a recurring product margin.
• Cash, cash equivalents and marketable securities totaled $2.379 billion at year-end, versus $1.690 billion at year-end 2020. Of the 2021 total, $434.0 million was held outside the United States. Restricted cash was $16.9 million and is separate.
• Cash used in investing was $1.035 billion, mainly reflecting net purchases of marketable securities ($953.7 million) and property and equipment ($81.7 million). Financing provided $250.9 million, including $213.3 million net proceeds from share issuance.
• The balance sheet reported $352.4 million of total liabilities, including $225.0 million of operating lease liabilities. The supplied filing data do not identify material borrowings or a debt balance.

Material changes and operating developments

• Revenue increased sharply from 2020, primarily because of the $900 million Vertex upfront payment. Net income reversed from a substantial loss in 2020 to profit in 2021; management cautions that losses are expected in future years.
• R&D expense rose $171.7 million year over year, reflecting higher variable program costs, facility expenses and employee-related costs. G&A increased $14.6 million, including higher employee and intellectual-property expenses.
• Under the April 2021 amended Vertex agreement, Vertex gained control of CTX001 development and commercialization, subject to CRISPR Therapeutics’ reserved rights. CTX001 profits and losses are allocated 40% to CRISPR Therapeutics and 60% to Vertex from July 1, 2021; the companies had shared them equally before then. CRISPR Therapeutics may receive a further $200 million upon the first FDA or European Commission marketing approval.
• At year-end, the company had 473 full-time employees. It completed construction of its Framingham cell-therapy facility and began regulatory validation activities; the facility was not yet described as validated for clinical production.

Clinical progress, outlook and risks

• CTX001: Enrollment was complete in the Phase 3 TDT and severe SCD trials, with more than 70 patients dosed across both studies as of the report. In the March 30, 2021 data cut, all 15 evaluable TDT patients were transfusion-independent at last follow-up; all seven evaluable SCD patients were free of vaso-occlusive crises through last analysis. These are early, limited follow-up results, not evidence of approval or established long-term durability.
• Safety: CTX001 safety findings were described as generally consistent with autologous stem-cell transplant and myeloablative conditioning. Reported serious events included events associated with busulfan and one TDT patient with serious events assessed as related or possibly related to CTX001; the reported events had resolved. Long-term monitoring is planned for up to 15 years.
• CTX110: In the CARBON Phase 1 trial, a single dose at dose level 2 or above produced a 58% overall response rate and 38% complete response rate on an intent-to-treat basis in the reported analysis. A 21% six-month complete-response rate was reported among the analyzed group, with some patients not yet reaching six months. The filing described the program as expanded into a pivotal trial with consolidation dosing; results remain early-stage.
• Management expects year-end cash and marketable securities to fund its current operating plan for at least 24 months, without assuming additional collaboration receipts or financing. This estimate depends on assumptions; the company expects ongoing losses and says it may need additional capital over the longer term.
• Key risks include uncertain clinical efficacy and long-term gene-editing safety, regulatory and manufacturing hurdles, trial enrollment and COVID-19 disruption, competition, partner reliance and control, and substantial intellectual-property uncertainty. U.S. patent interferences and European opposition proceedings involving core CRISPR rights were ongoing; the filing reported that a second in-licensed European patent was revoked in late 2021, with appeal pending.
• Management and the auditor reported effective internal control over financial reporting; the financial statements received an unqualified audit opinion. The auditor highlighted significant judgment in accounting for collaboration revenue and constrained milestone consideration.

Most important facts for investors to verify

• Reconcile the $900 million Vertex payment and confirm how much of reported earnings reflects nonrecurring collaboration accounting rather than ongoing economics.
• Review full financial statements and notes for cash, marketable-security composition, lease commitments, collaboration cost-sharing, and any obligations not captured by headline liquidity figures.
• Check subsequent CTX001 and CTX110 clinical updates, including patient counts, follow-up duration, durability, conditioning-related risks and serious adverse events.
• Track regulatory interactions, pivotal-trial design and timing, manufacturing validation, and whether any program requires additional studies before a marketing application.
• Monitor CRISPR patent proceedings and the practical effect of Vertex’s control of CTX001 development and the 40%/60% profit-and-loss allocation.